Observational Post-Authorisation Safety Study of Asenapine (Sycrest) (OBSERVA)

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2016 by Drug Safety Research Unit, Southampton, UK
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Professor Saad Shakir, Drug Safety Research Unit, Southampton, UK
ClinicalTrials.gov Identifier:
NCT01734278
First received: November 22, 2012
Last updated: January 25, 2016
Last verified: January 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: January 2017
  Estimated Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)